Akari Therapeutics (AKTX) Total Current Liabilities (2011 - 2026)

Akari Therapeutics' Total Current Liabilities history runs 13 years deep, the most recent figure standing at $13.4 million for Q1 2026.

• In Q1 2026, Total Current Liabilities fell 35.83% year-over-year to $13.4 million; the TTM figure through Mar 2026 stood at $13.4 million (down 35.83% YoY), while the FY2025 annual figure was $12.4 million, down 37.97% from the prior year.
• Total Current Liabilities came in at $13.4 million for Q1 2026 at Akari Therapeutics, up from $12.4 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $20.9 million in Q1 2025 to a low of $4.6 million in Q4 2023.
• A 4-year average of $12.8 million and a median of $12.9 million in 2025 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities surged 334.34% in 2024 and plunged 37.97% in 2025, its largest moves.
• Akari Therapeutics' Total Current Liabilities stood at $4.6 million in 2023, then soared by 334.34% to $19.9 million in 2024, then slumped by 37.97% to $12.4 million in 2025, then gained by 8.61% to $13.4 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $13.4 million, $12.4 million, and $15.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison